NCT00345540View on ClinicalTrials.gov

Efficacy of NOV-002 in Combination With Carboplatin in Chemotherapy-resistant Ovarian Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

July 31, 2006

Primary Completion Date

May 31, 2008

Study Completion Date

June 30, 2008

Conditions
Ovarian Cancer
Interventions
DRUG

NOV-002

60 mg / mL / day / 20-23 Days

DRUG

Carboplatin

AUC 5 following IV bolus administration of NOV-002

Trial Locations (2)

02115

Dana Farber Cancer/Partners Cancer Care, Boston

Massachusetts General Hospital, Boston

Sponsors
All Listed Sponsors
collaborator

Massachusetts General Hospital

OTHER

collaborator

Dana-Farber Cancer Institute

OTHER

lead

Cellectar Biosciences, Inc.

INDUSTRY

NCT00345540 - Efficacy of NOV-002 in Combination With Carboplatin in Chemotherapy-resistant Ovarian Cancer | Biotech Hunter | Biotech Hunter